Autopsy report · NCT05824455

A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors

“The sponsor voluntarily requested termination”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 6 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.

Sponsor type

Industry

Conditions

Advanced Solid Tumors

Interventions

JS109 combine with irinotecan

Participants

4

Sites

1

Countries

China

Trials that died the same way

• Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
  “Sponsor requested termination” (94% match in meaning)
• Evaluation of Cranioplasty Using Native Bone Autograft Versus Synthetic Bone Allograft
  “Sponsor termination” (88% match in meaning)
• Randomized Controlled Feasibility Trial of the Fearon Algorithm to Improve Management of Unstable Warfarin
  “Terminated by sponsor” (87% match in meaning)
• ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
  “Terminated - Sponsor Decision” (85% match in meaning)
• Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers
  “Sponsor Terminated” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.